What We're Reading: Page 385
Industry reads hand-picked by our editors
Dec 11, 2014
-
Business Standard
Indian company first to the finish line with historic Humira biosimilar
-
A $3B case of bad timing? Merck defends Cubist deal after judge invalidates patents
-
-
-
Feds refuse to hear Sandoz case related to biosimilar development efforts
-
-
After failed Allergan offensive, Valeant finally taking break from M&A focus
-
HHS extends legal immunity to Ebola vaccine makers
-
-
Bluebird shares skyrocket on promising gene therapy-blood disorder data
Dec 10, 2014
-
-
Feds drop wire fraud charges against former Lilly scientists
-
CEO of growing biopharma CRO killed in Maryland small jet crash
-
-
-
Pfizer creating gene therapy platform to expand rare disease efforts
-
-
-
Microsoft co-founder Allen donates $100M to unlock mysteries of the human cell
-
France, Germany, other EU countries suspend Indian generics approvals
Dec 09, 2014
-
Merck to buy antibiotics powerhouse Cubist for $9.5 billion
-
Why CRO employee turnover is still so high
-
FDA: A defined biosimlar pathway is coming—soon
-
Merck, BMS PD-1 drugs continue to roll, show promise for Hodgkin's lymphoma
-
-
-
-
-
Some more firsts for Incyte: Jakafi approved for chronic bone marrow disease
-
Dec 08, 2014
-
-
Big pharma meets medical marijuana? Dutch firm to build cannabinoid gum factory
-
-
The FDA's new effort to make it easier to create generics of risky drugs
-
-
-
Google's secretive Calico looking to hire bioinformatics pro
-
-
-
GSK reverses course, retracts plan to sell older drugs
Dec 05, 2014
-
Whistleblower: Sanofi, ex-CEO Viehbacher paid out $34M in kickback scheme
-
-
FDA OKs Amgen's Blincyto to treat rare form of acute lymphoblastic leukemia
-
Confirmed: GSK to chop 900 jobs, mostly in North Carolina, in massive reorg
-
-
Mice infused with human brain cells shed light on cognitive function
-
-
Beyond ABC: FDA finalizes labeling rules for pregnant, lactating women
-
-
Actavis to lay off 200 workers in California
-
Dec 04, 2014
-
Security firm: Hackers trying to manipulate global markets by stealing pharma emails
-
-
A $945 million breakup: J&J, Astellas call off major rheumatoid arthritis deal
-
-
Promising Biogen Alzheimer's drug leapfrogs from phase I to phase III
-
-
-
Puma Biotech plummets in after hours trading after delaying breast cancer NDA
-
-
Patent cliff ahead: Otsuka to buy Avanir for $3.5B and a slate of new products
Dec 03, 2014
-
-
Mylan strikes deal to make Gilead's HIV drugs more accessible to poor nations
-
-
Done deal: Pfizer completes acquistion of Baxter's vaccines
-
Why BMS is getting ready to slash up to 1,000 jobs in China
-
-
Meet the healthcare and pharma industry vet who will be Teva's next chairman
-
-
-
Despite deaths, Italian regulators declare Novartis flu vaccine safe—for now
Previous
